Screener
Intellia Therapeutics NTLA Income Statement
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| $7.66M-46.2% | $15.05M-9.5% | $23.02M+78.8% | $13.78M+51.3% | $14.25M+105% | ||
| $82.6M-14.9% | $80.74M-25.5% | $88.65M-24.1% | $94.75M-23.2% | $97.04M-15.0% | ||
| $37.82M+39.0% | $34.84M+20.1% | $33.08M+1.9% | $30.51M0.0% | $27.21M-14.4% | ||
| $120.42M-3.1% | $115.58M-15.9% | $121.73M-18.5% | $125.26M-18.6% | $124.24M-14.9% | ||
| -$112.76M-2.5% | -$100.53M+16.8% | -$98.71M+27.7% | -$111.48M+23.0% | -$110M+20.9% | ||
| -1,472.3%-700pp | -668.1%+58.5pp | -428.9%+631pp | -808.9%+780pp | -772.2%+1,226pp | ||
| $6.13M-29.9% | $4.3M-33.6% | $2.92M-61.3% | $10.15M+12.1% | $8.74M+210% | ||
| -$106.63M-5.3% | -$96.23M+15.8% | -$95.79M+25.7% | -$101.32M+25.3% | -$101.26M+31.1% | ||
| -1,392.3%-681pp | -639.5%+48.1pp | -416.2%+585pp | -735.2%+754pp | -710.8%+1,402pp | ||
| -$0.80+18.4% | -$0.81+26.4% | -$0.82+34.9% | -$0.92+31.3% | -$0.98+35.5% | ||
| -$110.66M-2.9% | -$98.33M+16.9% | -$96.33M+28.0% | -$109.08M+23.3% | -$107.5M+21.2% | ||
| -1,444.8%-690pp | -653.4%+58.1pp | -418.5%+621pp | -791.4%+769pp | -754.6%+1,207pp | ||
| -$112.76M-2.5% | -$100.53M+16.8% | -$98.71M+27.7% | -$111.48M+23.0% | -$110M+20.9% |
FAQ
- What is Intellia Therapeutics's revenue?
- Intellia Therapeutics (NTLA) generated $59.5M in revenue over the trailing twelve months, up 12.6% year over year.
- Is Intellia Therapeutics profitable?
- Intellia Therapeutics is not currently profitable: it reported a net loss of $400.0M over the trailing twelve months, a -672.2% net margin.
- What is Intellia Therapeutics's earnings per share?
- Intellia Therapeutics's diluted EPS over the trailing twelve months is $-3.35.
- Where does Intellia Therapeutics's income statement data come from?
- Every line is extracted from Intellia Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
